S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study
American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S395-S395
10.14309/01.ajg.0000776936.46186.11